Stargardt Disease Therapeutics Market Overview:
According to the research report published by DataM Intelligence 4Market Research, the global Stargardt Disease Therapeutics Market size was valued at USD XX billion in 2021, it is projected to reach USD XX billion by the end of 2029, with growth at a CAGR of 32% during the forecast period 2022-2029.
Stargardt disease is an attained juvenile macular degeneration that affects loss of vision. The disease falls into the uncommon disease type. There are several therapies in the pipeline which has not treatment existed to now.
Humans suffering from Stargardt disease may observe the black or grey color in the middle of their eyes, or eyes may be more sensitive to bright light. Others might even have signs of color blindness. Consent for some treatments that are presently in pipeline is predicted to drive the growth of the Global Stargardt Disease Therapeutics Market during the forecast period 2022-2029.
Market Growth Drivers:
Industry players are concentrating on several growth plans such as agreements and acquisitions to accelerate the progress of treatment for Stargardt disease, which is predictable to boost the market growth throughout the forecast period.
Additionally, players functioning in the global Stargardt disease therapeutics market are facing foremost challenges on numerous fronts owing to the COVID-19 pandemic. The key challenges comprise the supply of raw materials for manufacturing drug preparations owing to indiscretions in transportability.
The most important aspects that hamper Global Stargardt Disease Therapeutics Market growth contain the obtainability of replacements to restore vision in patients with Stargardt disease.
By Drug Type:
By Age Group:
- Children (Below 17 Years)
- Adult (Above 17 Years)
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
The adult segment is expected to account for the largest revenue share over the forecast period. The growth of the segment is due to the increasing number of patients with vision loss; increasing number of color-blind patients is expected to boost the forecast period.
According to the research study, published in March 2021, Stargardt disease is an autosomal recessive retinal dystrophy caused by mutations in the ABCA4 gene. It affects 1:8000 to 1:10,000 people worldwide, and patients generally develop central loss of vision in childhood or early adulthood. Moreover, ophthalmic examination classically shows bilateral atrophic changes in the macula because of the decline of photoreceptors and the retinal pigment epithelium (RPE) cells.
Download Sample Report @ https://www.datamintelligence.com/download-sample/stargardt-disease-therapeutics-market
North America – USA, and Canada
Europe – UK, London, Germany, Spain, Italy, and Other European Countries
Asia Pacific – India, China, Australia, Singapore, Japan, and Other Asia Pacific countries
The Middle East and Africa – UAE, KSA, Qatar, and South Africa
Regional Growth Insights:
North America Stargardt Disease Therapeutics Market is controlling the global market and predictable to account for the major revenue share in 2021. The high share is attributed to the growing number of product introductions and agreements related to Stargardt disease therapeutics by regulatory forms; the growing occurrence of Stargardt disease is anticipated to boost the market growth in the forecast period 2022-2029.
Competitive Growth Analysis:
In January 2021, Nanoscope Therapeutics Inc., a clinical-stage biotechnology company, received Orphan drug designation for vMCO-010, a gene therapy-based treatment for Stargardt disease, from the U.S. Food and Drug Administration (FDA). Thus, from the above statements, the North American region holds the largest market share.
The major players are adopting several growth strategies such as product development, acquisitions, and collaborations, which are contributing to the growth of the market globally.
Kubota Pharmaceutical Holdings Co., Ltd., Stargazer Pharmaceuticals Inc, Iveric Bio, Inc., Sanofi S.A., Alkeus Pharmaceuticals Inc, Astellas Pharma Inc., CHABiotech CO., Ltd., ReVision Therapeutics, Inc., Lin BioScience, Inc., Biogen Inc., and F. Hoffmann-La Roche AG.
Make an Inquiry before purchasing the full report @ https://www.datamintelligence.com/enquiry/stargardt-disease-therapeutics-market
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year, we have secured more than 100 unique customers from established organizations all over the world.
We monitor and analyze the market by dissecting various market influencers, competitive intensity, innovations, trends, and emerging products. This aids us in providing a detailed scenario of the present and future of the market.
DataM Intelligence 4Market Research LLP